Burkitt lymphoma (BL) is currently classified as one of three clinical variants: endemic BL, sporadic BL, and HIV-associated BL. The endemic variant is primarily diagnosed in sub-Saharan Africa and is epidemiologically associated with the Epstein–Barr virus (EBV) and malaria infection; although, the role of these pathogens in promoting the formation of BL remains unclear. On the other hand, sporadic BL is diagnosed outside of malaria-endemic areas, with only a minority of cases being EBV-positive (10-30%). This project seeks to generate high-throughput whole genome and transcriptome sequencing data from over 100 BL tumours in order to elucidate the genetic and molecular underpinnings of the disease. With this project, we aim to refine the mutational landscape of BL to facilitate the development of less toxic targeted therapies. We also plan on investigating the oncogenic role of EBV and whether it may serve as a better criterion for disease classification than the current system relying on geographic origin.